Disease · MONDO_0006846

malignant hypertension

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant hypertension. Diseases, record MONDO_0006846. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006846

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant hypertension; Open Targets
Open Targets ID: MONDO_0006846; Open Targets
Other names: Hypertension, Malignant, accelerated-malignant hypertension, hypertensive emergency, malignant phase hypertension; Open Targets
Disease Ontology: DOID:10824; Disease Ontology
MeSH: D006974; MeSH
Highest stage of its drugs: Approval, for 1 of its 9 drugs, from TTD; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRIMETHAPHAN	CHEMBL1201329	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CLEVIDIPINE	CHEMBL1237132	Small molecule	Phase 3	ClinicalTrials.gov	4	4	1	Drugs and targets
ECULIZUMAB	CHEMBL1201828	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NICARDIPINE HYDROCHLORIDE	CHEMBL1200326	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TONLAMARSEN	CHEMBL5095350	Oligonucleotide	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ESMOLOL	CHEMBL768	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE HYDROCHLORIDE	CHEMBL1200409	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
NICARDIPINE	CHEMBL1484	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1C	Voltage-gated L-type calcium channel	3	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	3	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	3	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	3	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/779	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 1	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 1	https://conductscience.org/library/genes/154	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 antagonist	Approval	https://conductscience.org/library/genes/1136	Drugs and targets
CHRNB4	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 antagonist	Approval	https://conductscience.org/library/genes/1143	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6336	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01951950	Nicardipine vs Esmolol Craniotomy Emergence	Phase 1	40	2014-08-29	Brain Tumors	ESMOLOL, NICARDIPINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04670809	Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies	Phase 3	262		Hypertensive Emergency	CLEVIDIPINE, NICARDIPINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT07511361	Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension	Phase 2	140		Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency	TONLAMARSEN	Its record names the disease	ClinicalTrials.gov
NCT03566329	Magnesium Sulphate Versus Lidocaine for Control of Emergence Hypertension	Phase 1	90		Craniotomy, Hypertension	LIDOCAINE HYDROCHLORIDE, MAGNESIUM SULFATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05726916	Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome	Phase 3	66		Hypertensive Emergency-associated Hemolytic Uremic Syndrome	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nicardipine vs Esmolol: serious adverse events	0 of 26	0 of 26	52	NCT01951950	Trial comparisons
Nicardipine vs Esmolol: Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg	1 of 20	11 of 20	40	NCT01951950	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
41231022	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006846

GET https://conductscience.org/api/diseases/v1/MONDO_0006846/drugs

API reference For AI assistants